CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Oral 25-Hydroxyvitamin D3Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2465 Telerehabilitation Wiki 0.50

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults

The goal of this clinical trial is to investigate the therapeutic efficacy of rapidly correcting vitamin D deficiency in adults with the use of 25-hydroxyvitamin D3 [25(OH)D3] for reducing the risk of acquiring the SARS-CoV-2 (COVID-19) viral infection and mitigating morbidity and mortality associated with this infection. This evidence-based hypothesis is related to several observations. Macrophages, activated T and B lymphocytes have a vitamin D receptor and 1,25-dihydroxyvitamin D3 induces defensin protein synthesis, influences immunoglobulin production and modulates T-cell cytokine production and functions. 1,25-dihydroxyvitamin D3 also reduces the angiotensin-converting enzyme 2 (ACE2) that is believed to serve as the binding site and gateway for COVID-19 to become infectious. This is a multicenter randomized3 doubleblinded placebo-controlled study aimed at determining the benefits of 25(OH)D3 treatment for the prevention of COVID-19 infection and improving clinical outcomes in infected patients. The investigators plan to recruit 1500 subjects in 3 study groups that include hospital health providers, patients with a positive test for COVID-19 and their relatives with a negative test. Eligible subjects in each study group with a documented serum level of 25(OH)D < 20 ng/mL will be randomized. Recruited subjects will be given 25 mcg of 25(OH)D3 daily or an identically appearing placebo at the time of randomization for two months. Three hospitals will participate and the sample size is foreseen to be equally distributed between the three. Since the clinical trial is designed as minimal risk a formal committee for data monitoring is not foreseen. However, potential toxicity will be monitored every 4 weeks with a serum calcium, albumin and creatinine by the PI and the study coordinators. If the corrected serum calcium increases above 10.6 mg/dl and a repeat confirms that the calcium is above 10.6 mg/dL the subject will be dropped from the study and referred to his or her PCP. Early signs and symptoms of vitamin D toxicity associated with hypercalcemia are increased thirst, increase in frequency of urination, especially at night. The subjects will be followed up weekly by phone to ask about their sign and symptoms.

NCT04386850 COVID 19 Drug: Oral 25-Hydroxyvitamin D3

Primary Outcomes

Description: Percentage of patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or patients with a COVID-19 positive test by the polymerase chain reaction (PCR)

Measure: COVID-19 (SARA-Cov-2) infection

Time: 60 days

Description: Percentage of mild, moderate and sever forms of COVID-19 based on WHO criteria

Measure: Severity of COVID-19 (SARA-Cov-2) infection

Time: 60 days

Description: Percentage of patients who need to be hospitalized

Measure: Hospitalization

Time: 60 days

Description: Days from the first symptom/positive test to discharge from hospital/negative test

Measure: Disease duration

Time: 60 days

Description: Rate of death due to COVID-19 during the study

Measure: Death

Time: 60 days

Description: Percentage of COVID patients who need oxygen support

Measure: Oxygen support

Time: 60 days

Secondary Outcomes

Description: Percentage of COVID patients who require each: Nasal cannula, Non-invasive ventilation or high-flow nasal cannula, Invasive mechanical ventilation, Invasive mechanical ventilation and ECMO

Measure: Type of oxygen support

Time: 60 days

Description: Percentage of COVID patients who display each: fever, dry cough, coughing sputum or blood, sore throat, headache, diarrhea and shortness of breath

Measure: Symptoms of COVID-19

Time: 60 days

Description: Serum Levels of 25-hydroxyvitamin D3 (ng/ml) by HPLC

Measure: Serum Levels of 25-hydroxyvitamin D3

Time: 60 days

Description: Serum calcium concentration (mg/dl)

Measure: Serum levels of calcium

Time: 60 days

Description: Serum phosphorus concentration (mg/dl)

Measure: Serum levels of phosphorus

Time: 60 days

Description: Serum creatinine concentration (mg/dl)

Measure: Serum levels of creatinine

Time: 60 days

Description: Serum albumin concentration (g/dl)

Measure: Serum levels of albumin

Time: 60 days

Description: Serum concentration of the blood urea nitrogen (mg/dl)

Measure: Serum levels of the blood urea nitrogen (BUN)

Time: 60 days

Description: Serum concentration of the parathyroid hormone (pg/ml)

Measure: Serum levels of the parathyroid hormone (PTH)

Time: 60 days


No related HPO nodes (Using clinical trials)